Want to see PRME full AI Analyst Report?
PRME Stock Chart & Stats
$3.58
$0.15(5.08%)
At close: 4:00 PM EDT
$3.58
$0.15(5.08%)
Day’s Range― - ―
52-Week Range$2.67 - $6.30
Previous CloseN/A
Volume304.95K
Average Volume (3M)4.12M
Market Cap
$654.77M
Enterprise Value$671.37M
Total Cash (Recent Filing)$95.07M
Total Debt (Recent Filing)$112.48M
Price to Earnings (P/E)―
Beta2.87
Next Earnings
Oct 30, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend Yield6.8%
Share Statistics
EPS (TTM)-1.10
Shares Outstanding181,376,860
10 Day Avg. Volume6,003,532
30 Day Avg. Volume4,122,861
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue164.83
Enterprise Value/Gross Profit-16.07
Enterprise Value/Ebitda-3.72
Forecast
1Y Price Target
$7.67Price Target Upside114.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$8.86M
Bulls Say, Bears Say
Bulls Say
Prime Editing PlatformPrime Medicine is built around a differentiated gene-editing approach intended to make precise DNA changes. If the platform translates into effective therapies, its underlying technology could support multiple programs and create durable strategic value beyond a single drug candidate.
Pipeline DevelopmentThe company is pursuing a platform-led pipeline rather than a single research program, with candidates progressing across discovery, preclinical, and clinical stages. This broader development model can diversify future opportunity and provide multiple paths for scientific and commercial progress.
Asset BaseDespite substantial losses and a weakening equity cushion, the company retains a sizable asset base of about $249 million. That resource base provides some support for ongoing research and development and offers greater operating capacity than the revenue scale alone would suggest.
Bears Say
Small, Declining RevenueRevenue remains very small relative to the company’s operating needs and declined materially from the prior period. This limited and volatile revenue base provides little internal funding for development, leaving the business dependent on future financing or successful program advancement.
Persistent Losses And Cash BurnHeavy recurring losses and deeply negative operating and free cash flow show that the business is consuming substantial cash while still in its investment phase. Continued burn increases funding requirements and reduces the company’s ability to sustain development without external capital.
Rising LeverageDebt has risen as the equity cushion has eroded sharply, producing a materially higher leverage profile. This weakens financial flexibility, increases pressure on future capital allocation, and makes continued operating losses more consequential for the company’s ability to fund its pipeline.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $2.67 and its highest was $6.30 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $654.77M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Oct 30, 2026 which is in 12 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.017.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.006 which represents an annual dividend yield of 6.8%. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 181,376,860 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -4.221%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (114.15% Upside)
$7.67 (114.15% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.17%
12-Months-Change
Fundamentals
Return on Equity
-188.27%
Trailing 12-Months
Asset Growth
-10.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$7.67
▲(114.15% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
13.25%
Insiders
7.21% Mutual Funds
0.36% Other Institutional Investors
65.01% Public Companies and
Individual Investors